文献速递炎症性肠病

早期维得利珠单抗谷浓度可预测炎症性肠病黏膜愈合:一项多中心前瞻性观察性研究

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-31

研究在法国三家转诊中心前瞻性纳入82例炎症性肠病患者,检测维得利珠单抗治疗第2、6、14周谷浓度,分析治疗第一年内黏膜愈合情况。仅第6周谷浓度在有无黏膜愈合患者间存在差异(26.8 vs 15.1 μg/mL,P=0.035),第6周谷浓度>18 μg/mL是黏膜愈合的唯一独立相关因素(OR 15.7,95%CI 2.4-173.0,P=0.01)。

要点

  • 第6周维得利珠单抗谷浓度>18 μg/mL与治疗第一年内黏膜愈合独立相关(OR 15.7)。
  • 第6周谷浓度预测黏膜愈合的AUC为0.735(95%CI 0.531-0.939)。
  • 第2周和第14周谷浓度在有无黏膜愈合患者间无显著差异。

核心结论

  • 早期治疗药物监测可能有助于及时识别需要强化给药方案的维得利珠单抗治疗患者。

研究设计与样本

  • 前瞻性观察性研究,在法国三家转诊中心于2014年6月1日至2017年3月31日期间纳入所有接受维得利珠单抗治疗的炎症性肠病患者,共82例。
  • 在维得利珠单抗治疗第2、6、14周采集谷浓度,分析治疗开始后第一年内接受磁共振成像和/或内镜黏膜评估的每例患者的结果。

主要发现

  • 总体人群(n=82)中位维得利珠单抗谷浓度在第2周为27 μg/mL(四分位距IQR 21.2-33.8 μg/mL),第6周为23 μg/mL(IQR 15-34.5 μg/mL),第14周为10.7 μg/mL(IQR 4.6-20.4 μg/mL)。
  • 仅第6周中位谷浓度在治疗第一年内有无黏膜愈合的患者间存在差异(26.8 vs 15.1 μg/mL,P=0.035)。
  • 第6周谷浓度18 μg/mL作为切点预测治疗第一年内黏膜愈合的受试者工作特征曲线下面积为0.735(95%置信区间0.531-0.939)。
  • 第6周维得利珠单抗谷浓度>18 μg/mL是治疗第一年内黏膜愈合的唯一独立相关变量(比值比15.7,95%置信区间2.4-173.0,P=0.01)。

关键数值与推荐

  • 第6周维得利珠单抗谷浓度>18 μg/mL与治疗第一年内黏膜愈合独立相关(OR 15.7,95%CI 2.4-173.0,P=0.01)。

临床怎么用

  • 早期治疗药物监测可能有助于及时识别需要强化给药方案的维得利珠单抗治疗患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The correlation between vedolizumab trough levels during induction therapy and mucosal healing remains unknown. AIM: To compare early vedolizumab trough levels in patients with and without mucosal healing within the first year after treatment initiation. METHODS: We prospectively collected vedolizumab trough levels in all inflammatory bowel disease patients at weeks 2, 6 and 14 of vedolizumab treatment in three French referral centres between 1 June 2014 and 31 March 2017. Results of every patient that underwent mucosal assessment by magnetic resonance imaging and/or endoscopy in the first year after treatment initiation were analysed. RESULTS: Median vedolizumab trough levels in the overall population (n = 82) were 27 μg/mL (interquartile range, IQR 21.2-33.8 μg/mL) at week 2, 23 μg/mL (IQR 15-34.5 μg/mL) at week 6 and 10.7 μg/mL (IQR 4.6-20.4 μg/mL) at week 14. Only median vedolizumab trough levels at week 6 differed between patients with and without mucosal healing within the first year after treatment initiation (26.8 vs 15.1 μg/mL, P = 0.035). A cut-off trough level of 18 μg/mL at week 6 predicted mucosal healing within the first year after the start of vedolizumab with an area under the receiver operating curve of 0.735 (95% confidence interval 0.531-0.939). A vedolizumab trough level above 18 μg/mL at week 6 was the only independent variable associated with mucosal healing within the first year of treatment (odds ratio 15.7, 95% confidence interval 2.4-173.0, P = 0.01). CONCLUSION: Early therapeutic drug monitoring might improve timely detection of vedolizumab-treated patients in need for an intensified dosing regimen.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018. PMID: 29384209. doi:10.1111/apt.14548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。